Data from Incyte’s Oncology Portfolio Accepted for Presentation at the 2021 ASCO Annual Meeting
20.5.2021 00:14:00 EEST | Business Wire | Press release
Incyte (Nasdaq: INCY) today announced that multiple abstracts highlighting data from its oncology portfolio will be presented during the upcoming 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, held virtually from June 4-8, 2021.
“We look forward to presenting data from across Incyte’s oncology portfolio and partner programs at this year’s ASCO Annual Meeting,” said Steven Stein, M.D., Chief Medical Officer, Incyte. “Data being presented during this congress, including new three-year data from the L-MIND study of tafasitamab in relapsed or refractory diffuse large B-cell lymphoma as well as results of the OPTIC study of ponatinib in chronic phase-chronic myeloid leukemia, underscore our continued focus on advancing science to help meet patients’ needs.”
Key abstracts accepted by ASCO include:
Oral Presentations
Ponatinib
OPTIC Primary Analysis: A Dose-Optimization Study of 3 Starting Doses of Ponatinib (PON)1 (Abstract #7000. Session: Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant.)
Poster Discussions
Tafasitamab
Long-Term Analyses from L-MIND, a Phase 2 Study of Tafasitamab (MOR208) Combined with Lenalidomide (LEN) in Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL)2 (Abstract #7513. Session: Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia.)
Capmatinib
Capmatinib in MET Exon 14-Mutated, Advanced NSCLC: Updated Results from the GEOMETRY Mono-1 Study3 (Abstract #9020. Session: Lung Cancer—Non-Small Cell Metastatic.)
ePosters
Capmatinib
Capmatinib Efficacy in Patients with NSCLC Identified as METex14 Using an NGS-Based Liquid Biopsy Assay: Results from the GEOMETRY Mono-1 Study3 (Abstract #9111. Session: Lung Cancer—Non-Small Cell Metastatic.)
Patient-Reported Outcomes in Capmatinib-Treated Patients with METex14-Mutated Advanced NSCLC: Results from the Phase 2 GEOMETRY Mono-1 Study3 (Abstract #9056. Session: Lung Cancer—Non-Small Cell Metastatic.)
Phase 1b/2 Study of Capmatinib Plus Gefitinib in Patients with EGFR-Mutated, MET-Dysregulated Non–Small Cell Lung Cancer who Received Prior Therapy: Final Overall Survival and Safety3 (Abstract #9048. Session: Lung Cancer—Non-Small Cell Metastatic.)
Pemigatinib
Pemigatinib for Previously Treated Locally Advanced/Metastatic Cholangiocarcinoma (CCA): Update of FIGHT-202 (Abstract #4086. Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary.)
Retifanlimab
Phase 2 Study of Retifanlimab (INCMGA00012) in Patients (Pts) with Selected Solid Tumors (POD1UM-203) (Abstract #2571. Session: Developmental Therapeutics—Immunotherapy.)
Ruxolitinib-Parsaclisib Combination Studies
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Ruxolitinib Plus Parsaclisib in Patients with JAK- and PI3K-Inhibitor Treatment–Naïve Myelofibrosis (Abstract #TPS7058. Session: Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant.)
Tafasitamab
A Phase 3 Study to Evaluate the Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Versus Placebo Plus Lenalidomide and Rituximab in Patients with Relapsed/Refractory (R/R) Follicular Lymphoma (FL) or Marginal Zone Lymphoma (MZL) (Abstract #TPS7568. Session: Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia.)
First-MIND: A Phase 1b, Open-Label, Randomized Study to Assess Safety of Tafasitamab (tafa) or Tafa + Lenalidomide (LEN) in Addition to R‑CHOP in Patients with Newly Diagnosed DLBCL2 (Abstract #7540. Session: Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia.)
For full session details and data presentation listings, please see the ASCO21 online program at https://meetinglibrary.asco.org. Oral, poster discussion and poster sessions, as well as track-based clinical science symposia, accepted for presentation at ASCO will be available on demand beginning Friday, June 4, 2021 at 9:00 a.m. ET.
About Incyte
Incyte is a Wilmington, Delaware-based, global biopharmaceutical company focused on finding solutions for serious unmet medical needs through the discovery, development and commercialization of proprietary therapeutics. For additional information on Incyte, please visit Incyte.com and follow @Incyte.
Forward-Looking Statements
Except for the historical information set forth herein, the matters set forth in this press release, including statements regarding the presentation of data from the Company’s or partner company’s ongoing clinical development pipeline, and whether or when any development compounds or combinations will be approved or commercially available for use in humans anywhere in the world outside of the already approved indications in specific regions, its presentation plans for the upcoming ASCO meeting and its goal of improving the lives of patients, contain predictions, estimates and other forward-looking statements.
These forward-looking statements are based on the Company’s current expectations and subject to risks and uncertainties that may cause actual results to differ materially, including unanticipated developments in and risks related to: unanticipated delays; further research and development and the results of clinical trials possibly being unsuccessful or insufficient to meet applicable regulatory standards or warrant continued development; the ability to enroll sufficient numbers of subjects in clinical trials and the ability to enroll subjects in accordance with planned schedules; the effects of the COVID-19 pandemic and measures to address the pandemic on the Company’s clinical trials, supply chain and other third-party providers, and development and discovery operations; determinations made by the FDA and other regulatory authorities outside of the United States; the Company’s dependence on its relationships with its collaboration partners; and other risks detailed from time to time in the Company’s reports filed with the Securities and Exchange Commission, including its annual report for the year ended December 31, 2020 and the quarterly report on Form 10-Q for the quarter ended March 31, 2021. The Company disclaims any intent or obligation to update these forward-looking statements.
1 Takeda-sponsored abstract.
2 MorphoSys-sponsored abstract.
3 Novartis-sponsored abstract.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210519005952/en/
Contact information
Media
Catalina Loveman
+1 302 498 6171
cloveman@incyte.com
Investors
Christine Chiou
+1 302 274 4773
cchiou@incyte.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SCP Standard Capital Partners AG Completes Its Strategic Shift Towards Defence Technology Through the Acquisition of Vanea Technologies GmbH and Nocturne Technologies GmbH – Plans to Change Its Name to VANEA AG25.8.2026 13:26:00 EEST | Press release
SCP Standard Capital Partners AG (“SCP” or the “Company”) has today agreed to acquire all shares in Vanea Technologies GmbH (“VANEA”) and Nocturne Technologies GmbH (“Nocturne”). The shares will be acquired by way of capital increases in kind, utilising the Authorised Capital 2026, in return for the issue of new shares and cash compensation. VANEA is a young technology company specialising in the development of defence solutions for the dawning era of autonomous warfare. Nocturne, based in Osnabrück – also known as Nocturne Defence – specialises in forward-looking solutions in the field of civil and military counter-UAS systems (drone defence). The purchase price for the acquisition of VANEA is in the low six-figure range and comprises a cash component and a share component. The purchase price for the acquisition of Nocturne comprises a cash component and a share component, which together amount to a figure in the high six-figure range. Going forward, the Company will focus on developi
INSEAD Marks the First Milestone in Its Europe Campus Re-imagination25.8.2026 13:07:00 EEST | Press release
INSEAD, The Business School for the World, yesterday inaugurated the Tour Desmarais, marking a major milestone in its Europe Campus Re-imagination (ECR)—a ten-year, €350 million investment totransform its campus in Fontainebleau for the future of business education and learning. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260825752920/en/ From left: Charles Desmarais, Maria Desmarais, Nicolas Desmarais, Paul Desmarais MBA'79, Helene Desmarais, Jean-Michel Wilmotte, Francisco Veloso, Paul Desmarais III MBA'10J, Borina Andrieu The inauguration took place in the presence of members of the Desmarais family, public officials, members of the INSEAD community, partners and distinguished guests from across the business, academic and philanthropic communities. Nestled within one of Europe's most iconic forests, the INSEAD Europe Campus has welcomed students, executives, researchers and entrepreneurs from around the world for more
CTC Global Expands Advanced Conductor Portfolio with ACCC® Plus Conductor25.8.2026 13:00:00 EEST | Press release
CTC Global, the world’s leading developer and manufacturer of high-capacity Advanced Conductors, today announced the introduction of the ACCC® Plus Conductor, an enhanced addition to the ACCC® Conductor family. Utilities are facing a new set of transmission planning challenges, as load growth, generation shifts, interconnection queues, permitting constraints, and evolving reliability requirements put increasing pressure on both existing and new transmission infrastructure. Utilities must quickly add capacity while managing project costs, clearance constraints, structure requirements, and long-term performance. Built on highly proven ACCC® Conductor Technology, the ACCC® Plus Conductor is designed to deliver greater mechanical performance, improved efficiency, and enhanced sag performance, while offering greater design flexibility for demanding transmission line applications. The new conductor option features a higher-strength, higher-modulus core than standard ACCC® Conductor, supporti
From Factory to Field: emnify Launches OEM Program with Free SGP.32 Bootstrap Connectivity25.8.2026 11:00:00 EEST | Press release
emnify, a global provider of cloud-native IoT connectivity, today announced a new program for original equipment manufacturers (OEMs) building connected products for international markets. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260825932817/en/ From Factory to Field with SGP.32 Bootstrap Connectivity The program addresses two common challenges for OEMs: testing and configuring devices that would otherwise leave the factory without connectivity and managing customer-specific physical SIMs throughout production and fulfilment. It enables OEMs to ship a single device SKU globally with built-in SGP.32 bootstrap connectivity, allowing each device to connect to the relevant device-management system for connectivity testing, configuration, and digital eSIM profile provisioning - from the factory onward. Free emnify SGP.32 bootstrap profiles are available for every connected device across an OEM’s production volumes - not on
Nessum Adoption Expands Across Global Energy-Management Infrastructure25.8.2026 11:00:00 EEST | Press release
Nessum Alliance*2 today announced the expansion of Nessum technology in commercial HVAC and smart grid applications through deployments by Alliance members Daikin Industries, Ltd. and Power Plus Communications AG (PPC). The Alliance also noted that cumulative worldwide shipments of LSI devices incorporating Nessum IP have surpassed six million units, according to Panasonic Holdings Corporation, the technology licensor, underscoring its maturity and market adoption. As energy management, digitalization, and sustainable infrastructure accelerate worldwide, organizations need communications networks that combine reliability and flexibility. By enabling high-speed IP communications over existing wiring, Nessum is expanding its role across energy-management applications. Deployments by Daikin and PPC demonstrate how IEEE 1901*3-based Nessum technology delivers value in real-world infrastructure environments, connecting systems, devices, and operational data across critical sectors. In the H
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom